4-溴-1-(苯基磺酰基)-1H-吲哚-5-醇 | 1022955-24-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-1-(苯基磺酰基)-1H-吲哚-5-醇
• 英文名称: 4-bromo-1-(phenylsulfonyl)-1H-indol-5-ol
• 英文别名: 1-(benzenesulfonyl)-4-bromoindol-5-ol
• CAS: 1022955-24-3
• 化学式: C₁₄H₁₀BrNO₃S
• 分子量: 352.208
• InChiKey: XSOQLDWGMDNRQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-溴-1-(苯基磺酰基)-1H-吲哚-5-醇 、 乙酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 4-bromo-1-(phenylsulfonyl)-1H-indol-5-yl acetate
  参考文献：
  名称：

  WO2008/54288

  摘要：

  公开号：
• 作为产物：
  描述：

  5-苄氧基吲哚 在 palladium 10% on activated carbon sodium hydroxide 、 N-溴代丁二酰亚胺(NBS) 、 甲酸铵 、 四丁基硫酸氢铵 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.5h， 生成 4-溴-1-(苯基磺酰基)-1H-吲哚-5-醇
  参考文献：
  名称：

  WO2008/54288

  摘要：

  公开号：

文献信息

• URAT1 INHIBITOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US20170290795A1

  公开（公告）日：2017-10-12

  Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R 1a , R 2a , R 6a , and R 7a represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, R 3a and R 8a form a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which R 3a and R 8a are bonded, R 4a and R 5a form a benzene ring together with two carbon atoms to which R 4a and R 5a are bonded or represent any of the groups represented by R 1a described above, W a represents CR 10a or N, and where, R 10a represents any of the groups represented by R 1a , X a represents an oxygen atom or a sulfur atom, Y a represents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Z a represents CO 2 H.)

  提供的是以下公式（III）所代表的化合物，该化合物的互变异构体或立体异构体，或者是作为痛风或高尿酸血症治疗剂的药用可接受盐或溶剂。（在公式（III）中，R1a、R2a、R6a和R7a代表氢原子、具有1至8个碳原子的烷基、具有1至8个碳原子的烷氧基或氰基，R3a和R8a形成苯环或含有1至3个杂原子（从氮原子、氧原子和硫原子中选择）的5元杂环，作为环构成元素，与R3a和R8a结合的两个碳原子一起，R4a和R5a与R4a和R5a结合的两个碳原子一起形成苯环，或代表上述R1a描述的任何基团，W代表CR10a或N，其中R10a代表上述R1a描述的任何基团，X代表氧原子或硫原子，Y代表具有1至8个碳原子的烷基链，其中烷基链可能被具有1至8个碳原子的烷基取代，且烷基链可能是直链或支链烷基链，支链烷基链可能由连接到相同或不同的碳原子的侧链形成3至7个成员环，与侧链结合的碳原子以及可能在其中间具有双键，并且Z代表CO2H。）
• Compounds
  申请人：Brandt Peter

  公开号：US20080176829A1

  公开（公告）日：2008-07-24

  The present invention relates to compounds of the formula (I) wherein A, X and R 1 to R 9 are as described herein; to pharmaceutical compositions comprising the said compounds; to processes for their preparation; and to the use of the compounds as medicaments against 5-HT 6 receptor-related disorders.

  本发明涉及式(I)的化合物，其中A，X和R1至R9如此描述; 包括含有所述化合物的制药组合物；其制备过程；以及将该化合物用作治疗5-HT6受体相关疾病的药物。
• Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders
  申请人：Proximagen Limited

  公开号：US07960374B2

  公开（公告）日：2011-06-14

  The present invention relates to compounds of the formula (I) wherein A, X and R1 to R9 are as described herein; to pharmaceutical compositions comprising the said compounds; to processes for their preparation; and to the use of the compounds as medicaments against 5-HT6 receptor-related disorders.

  本发明涉及式(I)的化合物，其中A、X和R1至R9如本文所述；涉及包含所述化合物的制药组合物；涉及其制备方法；以及将所述化合物用作治疗5-HT6受体相关疾病的药物。
• URAT1 inhibitor
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US10173990B2

  公开（公告）日：2019-01-08

  Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia. (In the Formula (III), R1a, R2a, R6a, and R7a represent a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, or a cyano group, R3a and R8a form a benzene ring or a 5-membered heteroaryl ring containing 1 to 3 heteroatoms, as a ring constituent element, selected from nitrogen atoms, oxygen atoms, and sulfur atoms together with two carbon atoms to which R3a and R8a are bonded, R4a and R5a form a benzene ring together with two carbon atoms to which R4a and R5a are bonded or represent any of the groups represented by R1a described above, Wa represents CR10a or N, and where, R10a represents any of the groups represented by R1a, Xa represents an oxygen atom or a sulfur atom, Ya represents an alkylene chain having 1 to 8 carbon atoms, and where, the alkylene chain may be substituted with an alkyl group having 1 to 8 carbon atoms and the alkylene chain may be a linear or branched alkylene chain, the branched alkylene chain may have a 3- to 7-membered ring formed by side chains bonded to carbon atoms which are the same as or different from each other, together with the carbon atoms to which the side chains are bonded and may have a double bond in the middle thereof, and Za represents CO2H).

  本发明提供了由下式（III）代表的化合物、该化合物的同分异构体或立体异构体或其药学上可接受的盐或溶液，用作痛风或高尿酸血症的治疗剂。(在式（III）中，R1a、R2a、R6a 和 R7a 代表氢原子、具有 1 至 8 个碳原子的烷基、具有 1 至 8 个碳原子的烷氧基或氰基，R3a 和 R8a 构成苯环或含有 1 至 3 个杂原子的 5 元杂芳基环，作为环组成元素、选自氮原子、氧原子和硫原子，与 R3a 和 R8a 键合的两个碳原子一起，R4a 和 R5a 与 R4a 和 R5a 键合的两个碳原子一起形成苯环，或代表上述 R1a 所代表的任何基团，Wa 代表 CR10a 或 N，其中、R10a 代表 R1a 所代表的任何基团，Xa 代表氧原子或硫原子，Ya 代表具有 1 至 8 个碳原子的亚烷基链，其中，亚烷基链可以被具有 1 至 8 个碳原子的烷基取代，亚烷基链可以是直链或支链亚烷基链、支链亚烷基链可具有一个 3 至 7 元环，该环由与彼此相同或不同的碳原子键合的侧链以及与侧链键合的碳原子形成，并可在其中间具有一个双键，Za 代表 CO2H）。
• 8-SULFONYL-L, 3, 4, 8-TETRAHYDR0-2H- [1, 4]OXAZEPINO [6, 7-E]INDOLE DERIVATIVES AND THEIR USE AS 5-HT6 RECEPTOR LIGANDS
  申请人：BIOVITRUM AB (publ)

  公开号：EP2091953A1

  公开（公告）日：2009-08-26